Menu

Sudan Virus Disease

Our team at IBT Bioservices has extensive experience in preclinical testing services to assess the viability and effectiveness of novel therapies against filorviruses including Ebola and Marburg viruses

Caused by

Sudan ebolavirus, which can cause severe and often fatal illness.

Transmission

Sudan virus is transmitted to humans from wild animals, and once introduced into the human population, it can spread through human-to-human transmission.

Symptoms

Sudden onset of fever, intense weakness, muscle pain, headache, and sore throat.

Virus Family

Member of the Ebolavirus genus within the Filoviridae family

Research with filoviruses requires high containment laboratories significantly increasing the cost and timeline of therapeutic development. Our expert team of scientists have developed surrogate pseudo type models to perform a major portion of the preclinical testing under BSL2 conditions. We further partner with state-of-the-art BSL-4 facilities to conduct preclinical testing using the authentic Ebola and Marburg viruses. IBT Bioservices is a world leader in producing and offering unique reagents for filovirus research. We offers a diverse array of products and services designed to facilitate filovirus research for Ebolavirus, Sudan ebolavirus, and Marburg virus strains.

Our comprehensive range includes

Pseudoviruses specifically tailored for neutralization assays

Antibodies essential for detection in ELISA and Western blotting

Virus-like particles and glycoproteins

Rest assured, our reagents are of exceptional quality, and they are available for purchase to support your research endeavors.

Our preclinical testing services for filoviruses encompass a wide range of assessments, including:

In Vitro Studies

We employ cellular and molecular techniques to evaluate the antiviral activity of potential drugs against Sudan virus. These studies help identify compounds that can effectively inhibit viral replication (pseudovirus neutralization assays) and reduce viral load, potentially slowing the progression of the disease. IBT offers products and services focused on Gulu and Boniface variants.

Formulation Development

We collaborate closely with pharmaceutical companies and researchers to optimize the formulation of potential Sudan virus treatments. This process involves ensuring stability, bioavailability, and targeted delivery to enhance the therapeutic potential of the treatments.

Animal Models

Our experienced researchers utilize appropriate animal models, such as mice or nonhuman primates, to mimic Sudan virus infection and assess the safety and efficacy of potential treatments. IBT has developed lethal infections using Ag129 transgenic mice, who are deficient in IFN-α/β and IFN-γ receptors, infected with pseudo filoviruses to allow data collection in a BSL-2 safety setting. For our efficacy models, we closely monitor key parameters such as survival rates, viral titers, and immune responses to evaluate the effectiveness of the tested therapies. Our in vivo studies provide valuable data on the treatment’s ability to control viral replication, reduce disease severity, and improve overall outcomes. Available Animal Species and Strains: AG129 Mice, BALB/c Mice,CD-1 Mice,Hartley Guinea Pig

Contact us today to learn more about how our preclinical testing services can accelerate the development of promising treatments for the Sudan virus. Together, let’s make a difference in saving lives and securing a healthier future in the battle against this highly infectious pathogen.

REFRENCE NUMBER: 22050

Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut wisi enim ad minim veniam, quis nostrud exerci tation ullamcorper suscipit lobortis nisl ut aliquip ex ea commodo consequat. 

REFRENCE NUMBER: 22050

Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut wisi enim ad minim veniam, quis nostrud exerci tation ullamcorper suscipit lobortis nisl ut aliquip ex ea commodo consequat. 

REFRENCE NUMBER: 22050

REFRENCES

https://pubmed.ncbi.nlm.nih.gov/25793502/
Refrence: 25793502
https://pubmed.ncbi.nlm.nih.gov/27160900/
Refrence: 27160900